secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0000950170-23-006999
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology reports Q4 net loss $30.7M; cash $282.9M; clinical milestones ahead
--------------------------------------------------------------------------------

- Q4 2022 GAAP net loss $30.7M ($0.75/sh) vs $28.4M ($0.70/sh) in Q4 2021.
- Full year 2022 GAAP net loss $123.5M ($3.03/sh) vs $83.5M ($2.07/sh) in 2021.
- Cash & investments $282.9M; $100M loan facility (drew $10M); runway through mid-2025.
- Key milestones: ASPEN-06 (gastric) and ASPEN-02 (MDS) data H2 2023; ASPEN-07 (UC) dosed Feb 2023.
- Board strengthened with Scott Garland; IND for ALTA-002 (Tallac) expected H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000095017023006999/0000950170-23-006999-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000095017023006999/alxo-20230309.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-006999

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer